Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May:54 Suppl 4:S261-5.
doi: 10.1093/cid/cir995.

Building capacity for the assessment of HIV drug resistance: experiences from the PharmAccess African Studies to Evaluate Resistance network

Raph L Hamers  1 , Elske Straatsma, Cissy Kityo, Carole L Wallis, Wendy S Stevens, Kim C E Sigaloff, Margaret Siwale, Francesca Conradie, Mariette E Botes, Kishor Mandaliya, Maureen Wellington, Akin Osibogun, Michèle van Vugt, Tobias F Rinke de Wit; PharmAccess African Studies to Evaluate Resistance
Affiliations

Building capacity for the assessment of HIV drug resistance: experiences from the PharmAccess African Studies to Evaluate Resistance network

Raph L Hamers et al. Clin Infect Dis. 2012 May.

Abstract

The PharmAccess African Studies to Evaluate Resistance (PASER) network was established as a collaborative partnership of clinical sites, laboratories, and research groups in 6 African countries; its purpose is to build research and laboratory capacity in support of a coordinated effort to assess population-level acquired and transmitted human immunodeficiency virus type-1 drug resistance (HIVDR), thus contributing to the goals of the World Health Organization Global HIV Drug Resistance Network. PASER disseminates information to medical professionals and policy makers and conducts observational research related to HIVDR. The sustainability of the network is challenged by funding limitations, constraints in human resources, a vulnerable general health infrastructure, and high cost and complexity of molecular diagnostic testing. This report highlights experiences and challenges in the PASER network from 2006 to 2010.

PubMed Disclaimer

Publication types

Substances